Clinical Study of Cannabidiol in Children and Adolescents With Fragile X Syndrome
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the
efficacy and safety of Cannabidiol (CBD) administered as ZYN002 for the treatment of children
and adolescent patients with Fragile X Syndrome (FXS). Eligible participants will participate
in up to an 18 week treatment period, where all participants will receive placebo or active
study drug. Patients ages 3 to < 18 years, will be eligible to participate.